Cytophage Technologies Announces COO Departure Amid Restructuring

Winnipeg, Manitoba — April 14, 2026 — Leads & Copy — Cytophage Technologies Ltd. (TSXV: CYTO; FSE: 70G) announced today that Heather Medwick, Chief Operating Officer, left the company effective March 31, 2026, due to a comprehensive corporate restructuring.

The corporate restructuring aims to streamline operations, reduce costs, and preserve the company’s financial resources.

Dr. Steven Theriault, Cytophage Chief Executive Officer and Director, thanked Ms. Medwick for her commitment and dedication throughout her years of service. He noted she led the day-to-day operations and administration for the past seven years and played a key role in taking the company public. He wished her well in her future endeavors.

A special committee of independent directors, previously announced on March 6, 2026, continues to evaluate strategic alternatives, including a strategic financing proposal. The committee remains focused on acting in the best interests of all Cytophage shareholders and maximizing value.

The Board of Directors has not set a timetable for this process, nor has it made any decisions regarding any potential strategic transaction. There is no assurance that this process will result in any transaction. The company does not intend to provide further updates unless additional disclosure is appropriate or required by law.

Cytophage Technologies is a biotechnology company focused on bacteriophage research, product development, and commercialization.

Bacteriophages are viruses that infect and kill bacteria, acting as natural alternatives to antibiotics. Cytophage modifies these natural predators to create safe and toxin-free solutions for large markets, initially focusing on animal health. The company uses a large library of phage strains to address antibiotic resistance, which the WHO predicts will be the leading cause of human mortality by 2050. Many countries have banned or limited preventative antibiotic use in animal production, and consumers are demanding organic and antibiotic-free products.

Source: Cytophage Technologies Ltd.